Lumipulse® G β-Amyloid Ratio (1-42/1-40) CSF

The Lumipulse G  β-Amyloid Ratio (1-42/1-40) is an in vitro cerebral spinal fluid (CSF) test that combines the results of Lumipulse G  β-Amyloid 1-42 and Lumipulse G  β-Amyloid 1-40 into a ratio of ß-Amyloid 1-42 to ß-Amyloid 1-40 concentration using the LUMIPULSE G1200. 

Contact sales for information
Lumipulse® G β-Amyloid 1-42 IRC

Product # 231432

3 x 14 Cartridges
Lumipulse® G β-Amyloid 1-42 Calibrators

Product # 234884

2 x 3 Concentrations
Lumipulse® G β-Amyloid 1-40 IRC

Product # 231753

3 x 14 Cartridges
Lumipulse® G β-Amyloid 1-40 Calibrators

Product # 234891

2 x 3 Concentrations
Lumipulse® β-Amyloid Controls

Product # 234907

2 x 3 Concentrations
For in vitro diagnostic use
Please contact your local Fujirebio representative for the availability of this product in your country.

Click here to navigate

  • Contact sales for information
  • Details
  • Citations
  • Documentation
  • Insights
  • Product inquiry
  • Webinars
  • Details

    Please note: precaution

    The Lumipulse G β-Amyloid Ratio (1-42/1-40) must be calculated using the results obtained from Lumipulse G β-Amyloid 1-42 and Lumipulse G β-Amyloid 1-40 on the same patient sample and same LUMIPULSE G1200 Analyzer. Use of another manufacturer's assays may result in significantly different ratios. β-amyloid 1-42 and β-amyloid 1-40 values determined on patient samples using other manufacturers’ assays cannot be interchangeably used to calculate the Lumipulse G β-Amyloid Ratio (1-42/1-40) which could lead to wrong diagnostic conclusions. The Lumipulse G β-Amyloid 1-42 assay should only be used with the Lumipulse G β-Amyloid 1-40 to calculate the ratio of β-amyloid 1-42 / β-amyloid 1-40. The Lumipulse G β-Amyloid 1-42 and Lumipulse G β-Amyloid 1-40 assays are not intended to be used individually.

     

    For more information, click here

  • Citations

    The BIOZ badges associated with Fujirebio products include peer-reviewed citations derived from scientific studies using Fujirebio products. Please note that the peer-reviewed citations do not reflect the regulatory status of Fujirebio products. Users should refer to the specific product documentation and any (clinical) claims made therein in order to ensure compliant use. For each country or geographic region, users must verify the related regulatory status of the Fujirebio product.

  • Insights

  • Product inquiry

    CAPTCHA

    The provision of your data implies your consent to the processing of your data in our database and, depending on the option you choose, to receiving our monthly newsletter by e-mail.

    For more information on how we process your personal data and regarding the rights you have in this respect, we refer to our privacy policy, which we hold at your disposal HERE.

    If you no longer wish to receive our newsletter, you have the option to unsubscribe via the ‘unsubscribe’ tool at the bottom of the newsletter. If you want to have your data removed from our database, please contact us at: privacy@fujirebio.com.

  • Past webinars